Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells.
Trolitazone is a new oral antidiabetic agent able to reduce lipid peroxidation. In this study we evaluated its effect on the susceptibility of LDL and HDL to in vitro oxidation induced by copper ions and endothelial cells. In Cu(++)-induced LDL modification, different amounts of troglitazone were added to aliquots of the same pool of plasma with subsequent ultracentrifuge separation of LDL and HDL. Differences in LDL and HDL susceptibility to in vitro oxidation with Cu(++) were studied by measuring the changes in fluorescence intensity (expressed as lag phase). LDL derived from plasma incubated with different amounts of troglitazone were also incubated with umbilical vein endothelial cells (HUVEC), the modification being monitored by LDL relative electrophoretic mobility and fluorescence. During Cu(++)- and HUVEC-induced LDL oxidation, the decay rate of vitamin E, and the potency of troglitazone as a radical scavenger in comparison with vitamin E were also studied. Troglitazone determined a significant, dose-dependent decrease in Cu(++)-induced LDL and HDL oxidation. Incubation with HUVEC was also followed by a progressive, significant decrease of LDL relative electrophoretic mobility and fluorescence intensity. During Cu(++)- and HUVEC-induced-LDL modification, troglitazone significantly reduced the rate of vitamin E decay. In this study we also demonstrated that under the same oxidative stress, troglitazone was much more potent as a radical scavenger than vitamin E. In conclusion, the results demonstrate that troglitazone can reduce LDL and HDL in vitro oxidation and that, during this process, it can protect vitamin E. In addition to ensuring blood glucose control, the drug may therefore be useful in inhibiting lipoprotein peroxidation.
Cominacini
L
L
Istituto di Semeiotica e Nefrologia Medica, Università di Verona, Italy.
Garbin
U
U
Pastorino
A M
AM
Campagnola
M
M
Fratta Pasini
A
A
Davoli
A
A
Rigoni
A
A
Lo Cascio
V
V
D001161:Arteriosclerosis / Q000378:metabolism*; D002478:Cells, Cultured; D002839:Chromans / Q000494:pharmacology*; D003300:Copper / Q000494:pharmacology; D003920:Diabetes Mellitus / Q000378:metabolism*; D004727:Endothelium / Q000166:cytology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D010084:Oxidation-Reduction / Q000187:drug effects; D013844:Thiazoles / Q000494:pharmacology*; D045162:Thiazolidinediones; D000077288:Troglitazone; D014810:Vitamin E / Q000378:metabolism
D002839:Chromans; D007004:Hypoglycemic Agents; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D013844:Thiazoles; D045162:Thiazolidinediones; D014810:Vitamin E; D003300:Copper; D000077288:Troglitazone